The dawn phenomenon is a condition recently described in patients with insulin-dependent diabetes mellitus (IDDM) that is characterized by abrupt increases in fasting levels of plasma glucose or insulin requirements or both between 5 and 9 a.m., in the absence of antecedent hypoglycemia. To determine its potential clinical relevance, we assessed its frequency and reproducibility in 20 patients with IDDM and in 13 patients with non-insulin-dependent diabetes mellitus (NIDDM) during overnight closed-loop (feedback-controlled) intravenous insulin infusion. After 6 a.m., plasma glucose levels increased similarly in NIDDM (89 +/- 2 mg per deciliter, midnight to 6 a.m., vs. 98 +/- 2 mg per deciliter, 6 to 9 a.m.; P less than 0.01). Insulin requirements increased at least 50 per cent for 1 1/2 hours in 77 per cent of patients with NIDDM and in 75 per cent of patients with IDDM. In five patients with IDDM who were studied on four occasions, the phenomenon occurred during 17 of the 20 observation periods, with insulin requirements after 6 a.m. increasing 225 +/- 34 per cent; coefficients of variation in individual patients ranged from 4 to 25 per cent. Thus, the dawn phenomenon occurs commonly in both NIDDM and IDDM, but its potential variability must be taken into consideration when one is attempting to adjust insulin doses.
This article has been cited by other articles:
Monnier, L., Colette, C.
(2009). Target for Glycemic Control: Concentrating on glucose. Diabetes Care
32: S199-S204
[Full Text]
Freckmann, G., Jovanovic, L., Baumstark, A., Haug, C., van der Helm, W.
(2008). The Circadian Study:: The Get-Up Phenomenon in Type 1 Diabetes. Diabetes Care
31: e85-e85
[Full Text]
Scrimgeour, K, Gresham, M J, Giles, L R, Thomson, P C, Wynn, P C, Newman, R E
(2008). Ghrelin secretion is more closely aligned to energy balance than with feeding behaviour in the grower pig. J Endocrinol
198: 135-145
[Abstract][Full Text]
Praet, S. F. E., van Loon, L. J. C.
(2007). Optimizing the therapeutic benefits of exercise in Type 2 diabetes. J. Appl. Physiol.
103: 1113-1120
[Abstract][Full Text]
Monnier, L., Colette, C., Dunseath, G. J., Owens, D. R.
(2007). The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes. Diabetes Care
30: 263-269
[Abstract][Full Text]
(2006). The Dawn Phenomenon. DOC News
3: 5-5
[Full Text]
Wittlin, S. D.
(2006). Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy. The Diabetes Educator
32: 39S-46S
[Full Text]
Carroll, M. F., Gutierrez, A., Castro, M., Tsewang, D., Schade, D. S.
(2003). Targeting Postprandial Hyperglycemia: A Comparative Study of Insulinotropic Agents in Type 2 Diabetes. J. Clin. Endocrinol. Metab.
88: 5248-5254
[Abstract][Full Text]
Miles, J. M., Wooldridge, D., Grellner, W. J., Windsor, S., Isley, W. L., Klein, S., Harris, W. S.
(2003). Nocturnal and Postprandial Free Fatty Acid Kinetics in Normal and Type 2 Diabetic Subjects: Effects of Insulin Sensitization Therapy. Diabetes
52: 675-681
[Abstract][Full Text]
Jayagopal, V., Kilpatrick, E. S., Jennings, P. E., Hepburn, D. A., Atkin, S. L.
(2002). Biological Variation of Homeostasis Model Assessment-Derived Insulin Resistance in Type 2 Diabetes. Diabetes Care
25: 2022-2025
[Abstract][Full Text]
la Fleur, S. E., Kalsbeek, A., Wortel, J., Fekkes, M. L., Buijs, R. M.
(2001). A Daily Rhythm in Glucose Tolerance: A Role for the Suprachiasmatic Nucleus. Diabetes
50: 1237-1243
[Abstract][Full Text]
Troisi, R. J., Cowie, C. C., Harris, M. I.
(2000). Diurnal Variation in Fasting Plasma Glucose: Implications for Diagnosis of Diabetes in Patients Examined in the Afternoon. JAMA
284: 3157-3159
[Abstract][Full Text]
Van Cauter, E., Polonsky, K. S., Scheen, A. J.
(1997). Roles of Circadian Rhythmicity and Sleep in Human Glucose Regulation. Endocr. Rev.
18: 716-738
[Abstract][Full Text]
Wise, S., Nielsen, M., Rizza, R.
(1997). Effects of Hepatic Glycogen Content on Hepatic Insulin Action in Humans: Alteration in the Relative Contributions of Glycogenolysis and Gluconeogenesis to Endogenous Glucose Production. J. Clin. Endocrinol. Metab.
82: 1828-1833
[Abstract][Full Text]
Johannsson, G., Marin, P., Lonn, L., Ottosson, M., Stenlof, K., Bjorntorp, P., Sjostrom, L., Bengtsson, B.-A.
(1997). Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure. J. Clin. Endocrinol. Metab.
82: 727-734
[Abstract][Full Text]
(1985). Questions and Answers. JAMA
253: 1325-1326
Previous
